CRSP250502C40000
- 0.20
- -0.15-42.86%
CRISPR Therapeutics Newsroom
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80
BMO Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $97
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $80
Crispr Therapeutics AG (CRSP) Receives a Buy From Bank of America Securities
Leerink Partners Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $60
Analysts' Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Applied Therapeutics (APLT)
Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $57
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $84
CRISPR Therapeutics Analyst Ratings
RBC Capital Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Cuts Target Price to $38
RBC Cuts Price Target on CRISPR Therapeutics to $38 From $48, Keeps Sector Perform, Speculative Risk
BMO Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $97
Buy Rating for Crispr Therapeutics AG Driven by Promising Clinical Data and Diversified Pipeline
CRISPR Therapeutics Analyst Ratings
Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $82
Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82
Crispr Therapeutics Is Maintained at Underweight by Morgan Stanley
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Raises Target Price to $32
Evercore ISI Group Upgrades CRISPR Therapeutics to Outperform, Raises Price Target to $99
CRISPR Therapeutics Analyst Ratings